AHL
CATX icon

Abel Hall LLC’s Perspective Therapeutics CATX Stock Holding History

Abel Hall LLC’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$78.4K Buy
22,994
+11,200
+95% +$42.3K 0.01% 861
2026
Q1 		$49.2K Buy
+11,794
New +$49.8K 0.01% 745

Other funds holding CATX

NWMG
Nicholson Wealth Management Group Charlestown, South Carolina $170M AUM 10.45% 1-Year Est. Return
WIM
WealthPlan Investment Management Omaha, Nebraska $2.01B AUM 27.28% 1-Year Est. Return
TWM
Trueblood Wealth Management Lima, Ohio $286M AUM 27.34% 1-Year Est. Return
TMWM
Taylor & Morgan Wealth Management Flint, Michigan $203M AUM 24.74% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
KWM
Koa Wealth Management Encinitas, California $147M AUM 18.41% 1-Year Est. Return
CWP
Curated Wealth Partners El Segundo, California $774M AUM 5.71% 1-Year Est. Return
ISB
Iowa State Bank Urbandale, Iowa $598M AUM 26.27% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Abel Hall LLC's CATX Position: Q2 2026 in Review

Abel Hall LLC increased its Perspective Therapeutics (CATX) stake by 95% in Q2 2026, buying an estimated $42.3K and bringing the position to 22,994 shares worth $78.4K. The position accounts for 0.01% of the portfolio, ranked #861.

Abel Hall LLC first reported a position in CATX in Q1 2026 and has held it in 2 quarters since. 23 funds tracked by Wall St. Rank hold CATX as of Q2 2026.

  • Abel Hall LLC held 22,994 shares of Perspective Therapeutics worth $78.4K as of Q2 2026.
  • Abel Hall LLC bought 11,200 Perspective Therapeutics shares in Q2 2026, an estimated $42.3K.
  • Perspective Therapeutics made up 0.01% of Abel Hall LLC's portfolio in Q2 2026, its #861 holding.
  • Abel Hall LLC first reported a position in Perspective Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 23 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q2 2026.

Based on Abel Hall LLC's 13F filing for Q2 2026, filed 24 Jul 2026.